Literature DB >> 30923139

Valproate and the Pregnancy Prevention Programme: exceptional circumstances.

Lance V Watkins1, Hannah R Cock2, Heather Angus-Leppan3, Rohit Shankar4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30923139      PMCID： PMC6428457          DOI： 10.3399/bjgp19X701897

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN： 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  10 in total

1.  Learning disability and contraceptive decision-making.

Authors:  Sam Rowlands
Journal:  J Fam Plann Reprod Health Care       Date:  2011-07

Review 2.  Managing anti-epileptic drug treatment in adult patients with intellectual disability: a serious conundrum.

Authors:  Z Doran; R Shankar; M R Keezer; C Dale; B McLean; M P Kerr; J Devapriam; J Craig; J W Sander
Journal:  Eur J Neurol       Date:  2016-04-23       Impact factor: 6.089

3.  Valproate, women, and exceptional circumstances.

Authors:  Heather Angus-Leppan; Rohit Shankar; Hannah Cock
Journal:  BMJ       Date:  2018-08-28

4.  Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.

Authors:  E Campbell; F Kennedy; A Russell; W H Smithson; L Parsons; P J Morrison; B Liggan; B Irwin; N Delanty; S J Hunt; J Craig; J Morrow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-01-20       Impact factor: 10.154

5.  Weighing the risks of valproate in women who could become pregnant.

Authors:  Heather Angus-Leppan; Rebecca S N Liu
Journal:  BMJ       Date:  2018-04-18

6.  Epilepsy in adults with intellectual disabilities: prevalence, associations and service implications.

Authors:  Catherine W McGrother; Sabyasachi Bhaumik; Catherine F Thorp; Agnes Hauck; David Branford; Joanna M Watson
Journal:  Seizure       Date:  2006-06-19       Impact factor: 3.184

7.  Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.

Authors:  Torbjörn Tomson; Dina Battino; Erminio Bonizzoni; John Craig; Dick Lindhout; Emilio Perucca; Anne Sabers; Sanjeev V Thomas; Frank Vajda
Journal:  Lancet Neurol       Date:  2018-04-18       Impact factor: 44.182

8.  Comparative safety of antiepileptic drugs during pregnancy.

Authors:  S Hernández-Díaz; C R Smith; A Shen; R Mittendorf; W A Hauser; M Yerby; L B Holmes
Journal:  Neurology       Date:  2012-05-02       Impact factor: 9.910

9.  Dose dependence of fetal malformations associated with valproate.

Authors:  Frank J Vajda; Terence J O'Brien; Janet E Graham; Cecilie M Lander; Mervyn J Eadie
Journal:  Neurology       Date:  2013-08-02       Impact factor: 9.910

Review 10.  Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child.

Authors:  Rebecca Bromley; Jennifer Weston; Naghme Adab; Janette Greenhalgh; Anna Sanniti; Andrew J McKay; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2014-10-30
  10 in total
  3 in total

1.  Valproate and the Pregnancy Prevention Programme.

Authors:  Sarah Morgan; June Raine; Ian Hudson
Journal:  Br J Gen Pract       Date:  2019-05       Impact factor: 5.386

Review 2.  Why won't it stop? The dynamics of benzodiazepine resistance in status epilepticus.

Authors:  Richard J Burman; Richard E Rosch; Jo M Wilmshurst; Arjune Sen; Georgia Ramantani; Colin J Akerman; Joseph V Raimondo
Journal:  Nat Rev Neurol       Date:  2022-05-10       Impact factor: 44.711

3.  Valproate prescription to women of childbearing age in English primary care: repeated cross-sectional analyses and retrospective cohort study.

Authors:  Mariangela Gaudio; Emmanouela Konstantara; Mark Joy; Jeremy van Vlymen; Simon de Lusignan
Journal:  BMC Pregnancy Childbirth       Date:  2022-01-27       Impact factor: 3.007
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.